NIV and CPAP Failure Predictors in COVID-19 Associated Respiratory Failure

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04342104

Enrollment

100

Registered

2020-04-10

Start date

2020-04-01

Completion date

2021-11-15

Last updated

2021-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid-19, Respiratory Failure

Keywords

noninvasive ventilation, CPAP, Covid-19, Respiratory failure, HACOR score

Brief summary

Detailed description

Evaluate HACOR socre utility and efficacy in predicting NIV and/or CPAP failure in patients with COVID-19 associated respiratory failure. Propose adaptations to HACOR score based on the state of art of COVID-19 \- this adaptations may include radiologic aggravation and monitoring of CRF, ferritin, LDH, d-dimers, NT-proBNP, troponin I, GOT, GPT, blood count

Interventions

OTHERMonitoring for aggravation

Monitor patients on CPAP or NIV and analyzing possible variables that may predict failure, namely: * lymphopenia * thrombocytopenia * CRP * ferritin * LDH * troponin I * NT-ProBNP * Liver enzymes * D-dimers * radiologic aggravation 1 day and 1 week after starting NIV or CPAP

OTHEREvaluate HACOR score effectivity in this patients

Apply the HACOR score after starting NIV and CPAP and later verify if it was effective in predicting NIV/CPAP failure

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients with acute respiratory failure due to COVID-19 who have initiated NIV or CPAP based on assistant clinician decision

Exclusion criteria

* Patients with imediate indication to invasive mechanical ventilation * Patients with any formal contraindication to noninvasive respiratory support

Design outcomes

Primary

Measure	Time frame	Description
HACOR score efficacy	1 hour after initation of CPAP or NIV	Analyze if HACOR score is effective in predicting nonivasive ventilation failure in COVID-19 associated respiratory failure
HACOR score addaptation	1 - 2 weeks	Analyze the role of possible variables to be added to HACOR score in order to improve efficay in COVID-19 patients

Countries

Spain

Contacts

Primary ContactMiguel Guia

miguelguia7@gmail.com00351915774975

Backup ContactAntonio Esquinas

antmesquinas@gmail.com0034609321966

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026